| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT00103272) | National Cancer Institute (NCI) | 2005-04-01 |
| Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00112853) | National Cancer Institute (NCI) | 2005-03-01 |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes (NCT00098826) | National Cancer Institute (NCI) | 2004-12-01 |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes (NCT00098423) | National Cancer Institute (NCI) | 2004-11-01 |
| XK469R in Treating Patients With Refractory Hematologic Cancer (NCT00095797) | National Cancer Institute (NCI) | 2004-10-01 |
| Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00101296) | National Cancer Institute (NCI) | 2004-10-01 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00101231) | National Cancer Institute (NCI) | 2004-10-01 |
| S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (NCT00093418) | National Cancer Institute (NCI) | 2004-09-01 |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00096122) | National Cancer Institute (NCI) | 2004-09-01 |
| Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies (NCT01056614) | Fred Hutchinson Cancer Center | 2004-09-01 |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00087204) | National Cancer Institute (NCI) | 2004-05-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011) | Fred Hutchinson Cancer Center | 2004-04-01 |
| CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase (NCT00084916) | National Cancer Institute (NCI) | 2004-04-01 |
| Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00079378) | National Cancer Institute (NCI) | 2004-02-01 |
| 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies (NCT00077181) | National Cancer Institute (NCI) | 2004-01-01 |
| Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia (NCT00085124) | National Cancer Institute (NCI) | 2003-12-01 |
| GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT00070551) | National Cancer Institute (NCI) | 2003-09-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00062075) | National Cancer Institute (NCI) | 2003-05-01 |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT00119366) | Fred Hutchinson Cancer Center | 2003-05-01 |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (NCT00060372) | National Cancer Institute (NCI) | 2003-04-01 |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation (NCT00052520) | Fred Hutchinson Cancer Center | 2002-09-01 |
| Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant (NCT00052598) | Fred Hutchinson Cancer Center | 2002-09-01 |
| Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00049582) | National Cancer Institute (NCI) | 2002-09-01 |
| A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) (NCT00045396) | National Cancer Institute (NCI) | 2002-06-01 |
| Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission (NCT00045435) | Fred Hutchinson Cancer Center | 2002-04-01 |
| Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia (NCT00039117) | National Cancer Institute (NCI) | 2002-04-01 |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (NCT00039091) | National Cancer Institute (NCI) | 2002-03-01 |
| Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer (NCT00049504) | Fred Hutchinson Cancer Center | 2002-01-01 |
| Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies (NCT00040846) | Fred Hutchinson Cancer Center | 2001-11-01 |
| Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (NCT00027872) | National Cancer Institute (NCI) | 2001-10-01 |
| Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer (NCT00012376) | National Cancer Institute (NCI) | 2001-03-01 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies (NCT00014235) | Fred Hutchinson Cancer Center | 2000-12-01 |
| Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (NCT00006363) | National Cancer Institute (NCI) | 2000-11-01 |
| Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia (NCT00093743) | Fred Hutchinson Cancer Center | 2000-01-01 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00005799) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission (NCT00005940) | Fred Hutchinson Cancer Center | 1999-10-01 |
| Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (NCT00008177) | Fred Hutchinson Cancer Center | 1999-07-27 |
| Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia (NCT00003190) | National Cancer Institute (NCI) | 1998-01-01 |
| High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma (NCT01177371) | Case Comprehensive Cancer Center | 1988-03-01 |
| Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (NCT01869803) | Wake Forest University Health Sciences | |